A new international study has found that a simple tablet treatment could improve survival rates for people with chronic ...

Morgan Stanley analyst Judah Frommer downgraded Galapagos (GLPG) to Underweight from Equal Weight with a price target of $22, down from $31.

In children, can being treated for cancer have consequences for the heart—namely, cardiac arrythmias? A new study by ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

Before I started my 30-year career as a pediatrician in Haywood County, I had the honor of spending many months from 1984 ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

NEW YORK – Galapagos said on Monday that it has partnered with NecstGen, a contract development and manufacturing organization (CDMO), to support decentralized manufacturing of Galapagos' cell therapy ...

Barrett told his grandma Honey, also known as Jill Lee, about the idea.

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.

Researchers observed an increase in both CXCR4 and CD5 levels as the cells progressed to later stages of the cell cycle, particularly in the S/G2/M phases.

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

Very sick patients who get a bone marrow transplant at Medical University of South Carolina survive at a much higher rate ...